Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03071692 · ClinicalTrials.gov registry record · Phase 3
Pemafibrate to Reduce Cardiovascular OutcoMes by Reducing Triglycerides IN patiENts With diabeTes (PROMINENT)
A Phase 3 study, sponsored by Kowa Research Institute.
- Terminated
- Registry status
- Phase 3
- Development phase
- 10,544
- Enrollment target
NCT03071692 is a Phase 3 study that was terminated before completion, run by Kowa Research Institute. The registered enrollment target is 10,544 participants.
The verdict
NCT03071692, a Phase 3 study, was terminated before completion, sponsored by Kowa Research Institute.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 10,544 participants
- Enrollment target
Study Summary
The primary objective of the study is to determine whether pemafibrate administered twice daily will delay the time to first occurrence of any component of the clinical composite endpoint of: * nonfatal Myocardial Infarction (MI) * nonfatal ischemic stroke * coronary revascularization; or * Cardio Vascular (CV) death.
Interventions
- DRUG Placebo
- DRUG K-877
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10,544 participants |
| Start Date | 2017-03-23 |
| Est. Completion | 2022-07-27 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03071692
The ClinicalTrials.gov registry entry for NCT03071692 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 10,544 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Kowa Research Institute, which has 44 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03071692 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03071692 about?
NCT03071692 is a clinical study titled "Pemafibrate to Reduce Cardiovascular OutcoMes by Reducing Triglycerides IN patiENts With diabeTes (PROMINENT)". The primary objective of the study is to determine whether pemafibrate administered twice daily will delay the time to first occurrence of any component of the clinical composite endpoint of: * nonfatal Myocardial Infarction (MI) * nonfatal ischemic stroke * coronary revascularization; or * Cardio ...
What is the current status of trial NCT03071692?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 10,544 participants. The study started on 2017-03-23. Estimated completion is 2022-07-27.
What interventions are being tested in trial NCT03071692?
The interventions under investigation include: Placebo (DRUG), K-877 (DRUG).
Who is sponsoring clinical trial NCT03071692?
This trial is sponsored by Kowa Research Institute, which has 44 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.